Qube Research & Technologies Ltd
Position in DMRA — Damora Therapeutics, Inc.
CIK 1729829
LONDON, X0
Position in DMRA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$7,315,092
New position
Shares Held
282,436
first reported quarter
Ownership
0.459%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Qube Research & Technologies Ltd holds $2,030,593,180 across 187 Biotechnology names. DMRA ranks #65 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
838,187 | $277,330,932 | |
| 2 | FOLD |
AMICUS THERAPEUTICS, INC.
|
8,809,340 | $127,383,056 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
3,450,904 | $95,590,040 | |
| 4 | RPRX |
Royalty Pharma plc
|
1,524,511 | $73,130,792 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
83,358 | $64,405,725 | |
| 6 | AXSM |
Axsome Therapeutics, Inc.
|
335,334 | $56,678,152 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
553,290 | $53,807,452 | |
| 8 | CYTK |
Cytokinetics Inc
|
779,446 | $51,373,285 |
All Filings in DMRA
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $7,315,092 | 282,436 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||